[Estrogen receptors beta--new target in cellular lung cancer treatment].
Literature review upon various types of estrogen receptors expression (type alpha and beta) in the cells of cellular lung cancer, their participation in estrogen and antiestrogen effects implementation, influence of estrogens and antiestrogens on occurrence and progression of malignant lung tumors in animals and humans. Were analyzed reasons of data ambiguity on type beta estrogen receptors (ERbeta) expression frequency. The results of authors own research in quantitative assessment of ERbeta expression in tumor tissue of patients with cellular lung cancer (79 male and 22 female patients are presented in this article. An increase in expression rate and incidence of tumors with high ERbeta level has been shown in patients with lung adenocarcinoma regardless of smoking status or gender. A new strategy of antiestrogen use, especially tamoxifen, has been formulated for cellular lung cancer treatment. Authors believe in a positive effect of adjuvant treatment with tamoxifen in patients with ERbeta-positive cellular lung cancer used independently or during and after the chemotherapy, by analogy with breast cancer patients.